Life Sciences Consulting & Advisory
Regulatory affairs, pharmacovigilance, and quality consulting firms supporting pharmaceutical and biotech clients.
- 4
- Verticals
Overview
Life Sciences Consulting & Advisory covers regulatory-affairs, pharmacovigilance, quality, and commercial-strategy consulting firms supporting pharmaceutical and biotech clients. It helps companies navigate FDA and global regulatory pathways, safety and quality requirements, and market access and commercialization.
Demand is driven by regulatory complexity, the volume of drug-development activity, and the specialized capability sponsors lack in-house. It overlaps clinical-research and commercial-analytics services (IQVIA and peers), and is consolidating as firms build scale across the development-to-commercialization journey.
Market snapshot
Not cleanly Census-coded — the mapped biotech-R&D code (541714, ~$91B) measures research activity, not consulting; life-sciences consulting proper sits within management/technical consulting, so it is not sized here.
Business model & economics
Revenue model
Advisory project and managed-service fees
Key economics
- Recurring revenue
- Moderate
- EBITDA margin
- 18–30%
- Capex intensity
- Low
recurring regulatory and pharmacovigilance work
Characteristics
- Navigates regulatory, safety, and market-access complexity.
- Demand tracks drug-development activity.
- Overlaps clinical-research and commercial-analytics services.
M&A deal context
Who’s acquiring
- Life-sciences-services platforms
- CRO & analytics strategics
- PE-backed advisory roll-ups
What’s driving deals
- Consolidation across development-to-commercialization services.
- Regulatory complexity driving demand.
- Drug-development-activity-driven volume.
Verticals in this segment
Find Life Sciences Consulting & Advisory acquisition targets
Search Acquisera’s index for companies classified under Life Sciences Consulting & Advisory (4.9.6) and build a targeted deal pipeline.
Search companies